Cancer Completely VANISHED!

The Clinical Trial with a 100 % Success Rate

A recent clinical study used Dostarlimab to treat locally advanced rectal cancer patients with mismatch repair deficiency (genetic mutation). The standard procedure in treating Rectal cancer involves neoadjuvant therapy, chemotherapy, chemoradiotherapy and surgery (1-3). These treatments can lead to life-altering long-term side effects, including bowel, urinary, sexual dysfunctions, and infertility. Patients with mismatch repair deficiency do not respond well to neoadjuvant chemotherapy (4-6) and need alternative options.

A small group of 12 participants were intravenously administered 500 mg of dostarlimab every three weeks for six months. The treatment was initially supposed to be followed up by radiotherapy and surgery (neoadjuvant process), but surprising results changed the action plan (7). All 12 patients completed treatment, at least 6 months of follow-up and had a clinical complete response, with no evidence of tumour (Figure 1).

Figure 1: Estimated percentages of viable tumor cells on pathological

examination before, during and follow‐up treatment (7).

The treatment was 100 % efficient in making the tumor completely disappear, meaning cancer became undetectable by physical exam, endoscopy, PET scans or M.R.I. scans in all 12 patients and stayed that way even after six months of follow-up. Figure 2 below shows the results of endoscopic evaluations, T2‐weighted MRI of the rectum, and 18F‐fluorodeoxyglucose–positron‐emission tomography (FDG‐PET) for one of the patients at baseline, at three months and six months. The patient had a complete response and a near‐complete response on T2‐weighted rectal MRI at three months and a complete clinical response at six months (7).


Figure 2: Evolution of Endoscopic and Radiographic Response in Representative Patients Treated with Dostarlimab (7).